InvestSMART

Aumake Limited (ASX:AUK)

ALERT: Price-sensitive ASX Announcement for AUK
Current share price for AUK : $0.003 0 (0%)+
Announcement
Release
27 Feb 2026 5:13PM
Price at Release
$0.003
Full Release
download
Summary
Aumake Limited's half-yearly report for the period ending December 31, 2025, outlines the company's financial performance and strategic changes. The company reported a decrease in sales revenue to $7.5 million, down from $13.6 million in the previous year, resulting in a net operating loss of $2.6 million. Key initiatives included a strategic placement raising $1.5 million in equity, involvement in the China OTC medicine market, and a $10 million distribution agreement with EZZ Life Sciences. The company focused on business streamlining to reduce overhead costs and improve financial control through new director appointments. Despite the losses and challenges, the company emphasized its efforts to maintain cash flow, raise capital, and continue operations, addressing risks related to management reliance, cash sufficiency, and international trade relations. The company plans to divest or wind up non-profitable joint ventures and continue focusing on its core market in China.
Key Points
  • Aumake Limited reported a sales revenue of $7.5 million for the half-year ended December 31, 2025.
  • The company incurred a net operating loss of $2.6 million.
  • A strategic placement raised $1.5 million in equity.
  • Entered the High Growth China OTC medicine market.
  • Secured a $10 million distribution agreement with EZZ Life Sciences.
  • Focus on business streamlining to reduce overhead costs.
  • Appointed new directors to improve governance and financial control.
  • Plans to divest or wind up non-profitable joint ventures.
  • Continued focus on the China market for sales and marketing of global brands.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.